Global COVID‑19 Vaccination Coverage & Post‑Vaccine Health Observations

This comprehensive article lists 50 countries with their COVID‑19 full vaccination rates and reports of any notable increases in specific medical conditions in subsequent years. The aim is to provide a well‑rounded, data‑driven perspective—vaccination remains a critical public health tool, and rare side effects must be acknowledged transparently.

Vaccination Coverage Table (50 Countries)

S.No.	Country	% Fully Vaccinated	Notable Post‑Vax Medical Signals?
1	China	87%	No signals outside narrow reports
2	Chile	86%	No signals
3	Singapore	85%	No signals
4	Norway	82%	Rare myocarditis; no other increase
5	Sweden	81%	No unusual signals
6	United Kingdom	81%	Rare CVST (AstraZeneca) + myocarditis
7	New Zealand	81%	No signals apart from very rare myocarditis
8	Canada	80%	Myocarditis (post‑mRNA), mild, rare
9	Portugal	79%	No unusual findings
10	Netherlands	79%	Low myocarditis; no other reports
11	Spain	79%	Myocarditis (limited cases), no other signal
12	Iceland	78%	No notable signals
13	Switzerland	78%	No new health signals
14	Italy	78%	Myocarditis; no new signals
15	Australia	78%	Myocarditis observed; no other signals
16	Ireland	76%	Post‑mRNA myocarditis
17	Germany	76%	Myocarditis; rare CVST
18	Argentina	76%	No unusual findings
19	Austria	75%	No signals beyond myocarditis
20	France	75%	Myocarditis in young males, mild
21	Qatar	73%	No signals
22	South Korea	73%	No major signals
23	Malaysia	72%	No signals
24	Greece	72%	Myocarditis rare
25	UAE	71%	No major findings
26	USA	69%	Myocarditis in young men; some rare clotting events
27	Colombia	69%	No verified signals
28	Brazil	68%	No conditions signal
29	Kuwait	68%	No signals
30	India	67%	No significant increase reported
31	Mexico	67%	No signals
32	Saudi Arabia	66%	No signals
33	Czechia	66%	No signals
34	Israel	64%	No broad signals
35	Japan	64%	No unusual signals
36	Turkey	62%	No major signals
37	Indonesia	60%	No signals
38	Philippines	60%	No signals
39	Hungary	60%	No new conditions noted
40	Russia	57%	No data on increased signals
41	Romania	57%	No signals
42	Pakistan	54%	No signals
43	Peru	53%	No major findings
44	Bangladesh	45%	No signals
45	South Africa	45%	No signals noted
46	Lebanon	44%	No medical increases
47	Nigeria	40%	No data on increased conditions
48	Bulgaria	40%	No verified increases
49	Egypt	35%	No signals
50	Kenya	30%	No evidence of increased conditions

Summary & Insights

Across the 50 countries with high to moderate vaccine coverage (45–87%), comprehensive surveillance systems identified only rare myocarditis and pericarditis in adolescent and young adult males—ranging from ~4 to 10 cases per million doses of mRNA vaccines. These were typically mild and resolved quickly with minimal treatment, such as rest or NSAIDs.

Very rare cases of cerebral venous sinus thrombosis (CVST) were linked to adenovirus-vector vaccines (e.g., AstraZeneca), primarily in younger women; the frequency is estimated at 1–2 cases per 100,000 doses.

Neurological events such as transverse myelitis, Guillain–Barré syndrome, or acute disseminated encephalomyelitis occurred, but only in isolated case studies.

Why These Data Support Continued Vaccination

• COVID‑19 disease itself carried much higher risk of myocarditis, thrombosis, and neurological complications—up to 10 times greater than vaccine risks.
• Vaccine protection reduced serious outcomes (hospitalization, ICU admission, death) by >90% in multiple high-quality studies.
• Large pharmacovigilance systems continue to monitor and find no signals of long-term adverse effects.

Implications & Responsible Use of Data

Transparency is crucial. Recognizing rare side effects builds trust, but does not negate the overwhelmingly positive benefit profile—including preventing many thousands of deaths per country and reducing long‑COVID incidence. Risk–benefit ratios remain strongly in favor of vaccine use.

Healthcare providers should inform patients, especially young males, about mild myocarditis risk and encourage reporting of any post‑vaccine symptoms like chest pain or palpitations.

Methodology

Vaccination statistics are sourced from WHO, UNICEF, and national health ministry dashboards (up to June 2025). Post-vaccination health signals derive from:

• Peer-reviewed research in journals like NEJM, The Lancet
• Government surveillance systems (CDC VAERS, EudraVigilance, GACVS)
• Public health agency safety updates (CDC, EMA, UK HSA)

This dataset of 50 countries confirms a consistent pattern: widespread vaccination (45–87%) accompanied by extremely rare and generally mild side effects. There is no evidence of broad increases in serious conditions post‑vaccination. Meanwhile, vaccines have prevented millions of deaths, hospitalizations, and cases of long‑COVID worldwide.

Vaccination remains one of the safest and most effective public health interventions. Awareness of rare effects allows for better clinical care and reinforces trust. The numbers strongly support continued vaccine campaigns—and informed communication should remain the priority.

Disclaimer: This article encourages vaccination and aims to inform readers with balanced, evidence-based facts. It is not intended to deter immunization.